147 related articles for article (PubMed ID: 20466523)
1. Blood-brain barrier penetration of the enantiomers of venlafaxine and its metabolites in mice lacking P-glycoprotein.
Karlsson L; Schmitt U; Josefsson M; Carlsson B; Ahlner J; Bengtsson F; Kugelberg FC; Hiemke C
Eur Neuropsychopharmacol; 2010 Sep; 20(9):632-40. PubMed ID: 20466523
[TBL] [Abstract][Full Text] [Related]
2. Effects on enantiomeric drug disposition and open-field behavior after chronic treatment with venlafaxine in the P-glycoprotein knockout mice model.
Karlsson L; Hiemke C; Carlsson B; Josefsson M; Ahlner J; Bengtsson F; Schmitt U; Kugelberg FC
Psychopharmacology (Berl); 2011 May; 215(2):367-77. PubMed ID: 21191569
[TBL] [Abstract][Full Text] [Related]
3. Differential enhancement of antidepressant penetration into the brain in mice with abcb1ab (mdr1ab) P-glycoprotein gene disruption.
Uhr M; Grauer MT; Holsboer F
Biol Psychiatry; 2003 Oct; 54(8):840-6. PubMed ID: 14550684
[TBL] [Abstract][Full Text] [Related]
4. Role of CYP2D6 in the stereoselective disposition of venlafaxine in humans.
Eap CB; Lessard E; Baumann P; Brawand-Amey M; Yessine MA; O'Hara G; Turgeon J
Pharmacogenetics; 2003 Jan; 13(1):39-47. PubMed ID: 12544511
[TBL] [Abstract][Full Text] [Related]
5. Concentrations of venlafaxine and its main metabolite O-desmethylvenlafaxine during pregnancy.
ter Horst PG; Larmené-Beld KH; Bosman J; van der Veen EL; Wieringa A; Smit JP
J Clin Pharm Ther; 2014 Oct; 39(5):541-4. PubMed ID: 24989434
[TBL] [Abstract][Full Text] [Related]
6. Blood-brain barrier penetration and pharmacokinetics of amitriptyline and its metabolites in p-glycoprotein (abcb1ab) knock-out mice and controls.
Uhr M; Grauer MT; Yassouridis A; Ebinger M
J Psychiatr Res; 2007; 41(1-2):179-88. PubMed ID: 16387324
[TBL] [Abstract][Full Text] [Related]
7. Induction of drug efflux protein expression by venlafaxine but not desvenlafaxine.
Bachmeier CJ; Beaulieu-Abdelahad D; Ganey NJ; Mullan MJ; Levin GM
Biopharm Drug Dispos; 2011 May; 32(4):233-44. PubMed ID: 21446053
[TBL] [Abstract][Full Text] [Related]
8. Influence of CYP2D6 genotype on the disposition of the enantiomers of venlafaxine and its major metabolites in postmortem femoral blood.
Kingbäck M; Karlsson L; Zackrisson AL; Carlsson B; Josefsson M; Bengtsson F; Ahlner J; Kugelberg FC
Forensic Sci Int; 2012 Jan; 214(1-3):124-34. PubMed ID: 21840145
[TBL] [Abstract][Full Text] [Related]
9. Stereoselective determination of venlafaxine and its three demethylated metabolites in human plasma and whole blood by liquid chromatography with electrospray tandem mass spectrometric detection and solid phase extraction.
Kingbäck M; Josefsson M; Karlsson L; Ahlner J; Bengtsson F; Kugelberg FC; Carlsson B
J Pharm Biomed Anal; 2010 Nov; 53(3):583-90. PubMed ID: 20435422
[TBL] [Abstract][Full Text] [Related]
10. abcb1ab P-glycoprotein is involved in the uptake of citalopram and trimipramine into the brain of mice.
Uhr M; Grauer MT
J Psychiatr Res; 2003; 37(3):179-85. PubMed ID: 12650738
[TBL] [Abstract][Full Text] [Related]
11. Melperone is an inhibitor of the CYP2D6 catalyzed O-demethylation of venlafaxine.
Grözinger M; Dragicevic A; Hiemke C; Shams M; Müller MJ; Härtter S
Pharmacopsychiatry; 2003 Jan; 36(1):3-6. PubMed ID: 12649767
[TBL] [Abstract][Full Text] [Related]
12. A short-term double-blind randomized controlled pilot trial with active or placebo pindolol in patients treated with venlafaxine for major depression.
Martiny K; Lunde M; Bech P; Plenge P
Nord J Psychiatry; 2012 Jun; 66(3):147-54. PubMed ID: 22458638
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic interaction between multiple-dose venlafaxine and single-dose lithium.
Troy SM; Parker VD; Hicks DR; Boudino FD; Chiang ST
J Clin Pharmacol; 1996 Feb; 36(2):175-81. PubMed ID: 8852394
[TBL] [Abstract][Full Text] [Related]
14. Nifedipine Does Not Alter the Pharmacokinetics of Venlafaxine Enantiomers in Healthy Subjects Phenotyped for CYP2D6, CYP2C19, and CYP3A.
Tozatto E; Benzi JRL; Rocha A; Coelho EB; Lanchote VL
J Clin Pharmacol; 2021 Mar; 61(3):319-327. PubMed ID: 32974907
[TBL] [Abstract][Full Text] [Related]
15. Influence of CYP2D6 activity on the disposition and cardiovascular toxicity of the antidepressant agent venlafaxine in humans.
Lessard E; Yessine MA; Hamelin BA; O'Hara G; LeBlanc J; Turgeon J
Pharmacogenetics; 1999 Aug; 9(4):435-43. PubMed ID: 10780263
[TBL] [Abstract][Full Text] [Related]
16. Establishing bioequivalence of racemic venlafaxine formulations using stereoselective assay method: Is it necessary?
Kandhwal K; Dey S; Nazarudheen S; Reyar S; Mishra S; Thudi NR; Khuroo AH; Monif T
Chirality; 2011 Nov; 23(10):948-54. PubMed ID: 21953854
[TBL] [Abstract][Full Text] [Related]
17. Donepezil, a cholinesterase inhibitor used in Alzheimer's disease therapy, is actively exported out of the brain by abcb1ab p-glycoproteins in mice.
Spieler D; Namendorf C; Namendorf T; von Cube M; Uhr M
J Psychiatr Res; 2020 May; 124():29-33. PubMed ID: 32114029
[TBL] [Abstract][Full Text] [Related]
18. Venlafaxine in human breast milk and nursing infant plasma: determination of exposure.
Newport DJ; Ritchie JC; Knight BT; Glover BA; Zach EB; Stowe ZN
J Clin Psychiatry; 2009 Sep; 70(9):1304-10. PubMed ID: 19607765
[TBL] [Abstract][Full Text] [Related]
19. Distribution of venlafaxine, O-desmethylvenlafaxine, and O-desmethylvenlafaxine to venlafaxine ratio in postmortem human brain tissue.
Murrell MD; Cruz DA; Javors MA; Thompson PM
J Forensic Sci; 2014 May; 59(3):683-9. PubMed ID: 24502274
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of venlafaxine extended release 75 mg and desvenlafaxine 50 mg in healthy CYP2D6 extensive and poor metabolizers: a randomized, open-label, two-period, parallel-group, crossover study.
Nichols AI; Focht K; Jiang Q; Preskorn SH; Kane CP
Clin Drug Investig; 2011; 31(3):155-67. PubMed ID: 21288052
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
